Atea reports high efficacy in Phase 2 HCV treatment study

Atea Pharmaceuticals, Inc. (NASDAQ: AVIR), a $294 million market cap biopharmaceutical company focusing on the development of oral antiviral therapies, announced today that its Phase 2 clinical study for a hepatitis C treatment regimen met its primary endpoints.